Kraig Biocraft Laboratories' Lead Sericulture Expert Joins Recombinant Spider Silk Production Team at New Rearing Facility in Southeast Asia
Kraig Biocraft Laboratories (OTCQB: KBLB), a biotechnology company specializing in spider silk technology, announced that Dr. Nirmal Kumar, their lead sericulture expert, has joined the production team at their new Southeast Asian rearing facility.
Dr. Kumar will oversee the first production cycle at the new center, focusing on BAM-1 spider silk production. His responsibilities include supervising the development of an expanded BAM-1 egg production center and testing lab. The company is also exploring partnerships with secondary processing providers and is in discussions with a potential customer regarding a custom spider silk thread order.
This development marks a significant step in Kraig Labs' transition to continuous production of their first recombinant spider silk hybrid line, positioning the company to meet growing market demand.
Kraig Biocraft Laboratories (OTCQB: KBLB), una società biotecnologica specializzata nella tecnologia della seta di ragno, ha annunciato che il Dr. Nirmal Kumar, loro esperto principale in sericoltura, si è unito al team di produzione del nuovo impianto di allevamento nell’Asia sudorientale.
Il Dr. Kumar supervisionerà il primo ciclo produttivo del nuovo centro, con particolare attenzione alla produzione di seta di ragno BAM-1. Tra le sue responsabilità c’è la supervisione dello sviluppo di un centro ampliato per la produzione di uova BAM-1 e di un laboratorio di prova. L’azienda sta inoltre esplorando collaborazioni con fornitori per la lavorazione secondaria ed è in trattativa con un potenziale cliente per un ordine personalizzato di fili di seta di ragno.
Questo sviluppo rappresenta un passo importante nella transizione di Kraig Labs verso una produzione continua della loro prima linea ibrida di seta di ragno ricombinante, posizionando l’azienda per soddisfare la crescente domanda di mercato.
Kraig Biocraft Laboratories (OTCQB: KBLB), una empresa biotecnológica especializada en tecnología de seda de araña, anunció que el Dr. Nirmal Kumar, su experto principal en sericultura, se ha incorporado al equipo de producción de su nueva instalación de cría en el sudeste asiático.
El Dr. Kumar supervisará el primer ciclo de producción en el nuevo centro, centrado en la producción de seda de araña BAM-1. Sus responsabilidades incluyen supervisar el desarrollo de un centro ampliado de producción de huevos BAM-1 y un laboratorio de pruebas. La compañía también está explorando alianzas con proveedores de procesamiento secundario y mantiene conversaciones con un cliente potencial sobre un pedido personalizado de hilo de seda de araña.
Este avance marca un paso significativo en la transición de Kraig Labs hacia la producción continua de su primera línea híbrida de seda de araña recombinante, posicionando a la empresa para satisfacer la creciente demanda del mercado.
Kraig Biocraft Laboratories (OTCQB: KBLB), 거미줄(실크) 기술을 전문으로 하는 생명공학 회사는 수의학(양잠) 분야의 수석 전문가 Dr. Nirmal Kumar이 동남아시아 신 육성(사육) 시설의 생산팀에 합류했다고 발표했습니다.
Dr. Kumar는 신규 센터의 첫 생산 주기를 총괄하며 BAM-1 거미 실크 생산에 중점을 둘 예정입니다. 그의 책임에는 확장된 BAM-1 난자(알) 생산 센터와 시험 연구소의 개발 감독이 포함됩니다. 회사는 또한 2차 가공 업체와의 파트너십을 모색 중이며, 맞춤형 거미실(hilo) 주문과 관련해 잠재 고객과 협의 중입니다.
이번 조치는 Kraig Labs가 최초의 재조합 거미 실크 하이브리드 라인의 연속 생산으로 전환하는 데 있어 중요한 진전으로, 회사가 증가하는 시장 수요를 충족할 수 있는 위치에 서게 합니다.
Kraig Biocraft Laboratories (OTCQB: KBLB), une société de biotechnologie spécialisée dans la technologie de la soie d’araignée, a annoncé que le Dr Nirmal Kumar, leur expert principal en sériciculture, a rejoint l’équipe de production de leur nouvelle installation d’élevage en Asie du Sud-Est.
Le Dr Kumar supervisera le premier cycle de production du nouveau centre, en se concentrant sur la production de soie d’araignée BAM-1. Ses responsabilités incluent la supervision du développement d’un centre élargi de production d’œufs BAM-1 et d’un laboratoire d’essais. La société étudie également des partenariats avec des prestataires de transformation secondaire et est en discussion avec un client potentiel au sujet d’une commande personnalisée de fil de soie d’araignée.
Cette avancée marque une étape importante dans la transition de Kraig Labs vers la production continue de leur première gamme hybride de soie d’araignée recombinante, positionnant l’entreprise pour répondre à la demande croissante du marché.
Kraig Biocraft Laboratories (OTCQB: KBLB), ein Biotechnologieunternehmen, das sich auf Spinnenseidetechnologie spezialisiert hat, gab bekannt, dass Dr. Nirmal Kumar, ihr leitender Seidenzucht-Experte, dem Produktionsteam ihrer neuen Aufzuchtanlage in Südostasien beigetreten ist.
Dr. Kumar wird den ersten Produktionszyklus im neuen Zentrum leiten und sich auf die BAM-1 Spinnenseidenproduktion konzentrieren. Zu seinen Aufgaben gehört die Beaufsichtigung des Ausbaus eines BAM-1-Ei-Produktionszentrums sowie eines Testlabors. Das Unternehmen prüft zudem Partnerschaften mit Anbietern für die Weiterverarbeitung und führt Gespräche mit einem potenziellen Kunden über eine kundenspezifische Bestellung von Spinnenseidenfäden.
Diese Entwicklung stellt einen bedeutenden Schritt in Kraig Labs’ Übergang zur kontinuierlichen Produktion ihrer ersten rekombinanten, hybriden Spinnenseidenlinie dar und positioniert das Unternehmen, um die wachsende Marktnachfrage zu bedienen.
- Expansion of production capabilities with second rearing facility now fully operational
- Potential customer discussions underway for custom spider silk thread order
- Development of expanded BAM-1 egg production center and testing lab to support scale-up
- Strategic exploration of secondary processing partnerships in the region
- Production scale remains unspecified and unproven
- No concrete timeline provided for commercial production targets
- Customer discussions still in preliminary stages without confirmed orders
ANN ARBOR, Mich., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, today announced that Dr. Nirmal Kumar, the Company's lead sericulture expert, has arrived in Southeast Asia to support the production team at its recently established second rearing facility.
Dr. Kumar will work directly with the Company's operations team on the first production cycle at the new center, ensuring the highest levels of quality and efficiency as Kraig Labs continues to expand its BAM-1 spider silk output. His expertise in silkworm rearing and hybrid development has been instrumental to the Company's success, and his on-site leadership marks a significant step for Kraig Labs in its transition to continuous production of BAM-1, its first recombinant spider silk hybrid line.
During this time with the team, Dr. Kumar will also oversee the build-out of an expanded BAM-1 egg production center and testing lab, designed to support ongoing scale-up and maintain production continuity across multiple rearing centers. These facilities will form the backbone of the Company's long-term commercialization strategy as Kraig Labs ramps BAM-1 production to meet growing demand.
Additionally, Dr. Kumar will explore opportunities with secondary processing providers in the region, including spinners capable of supporting downstream applications for recombinant spider silk. As part of this effort, Kraig Labs is currently in discussions with a potential customer regarding a custom order of spider silk thread, a crucial step toward demonstrating the versatility and scalability of BAM-1 in specialty textile markets.
"Having Dr. Kumar on the ground with our production team at this critical stage provides invaluable expertise with our second rearing center now fully online," said Kim Thompson, Kraig Labs' Founder and CEO. "His leadership not only strengthens our current BAM-1 production cycle but also sets the stage for the expansion and processing partnerships that will allow us to meet near-term customer opportunities and long-term market demand."
The Company's ability to execute on both upstream production and downstream processing highlights its unique position at the intersection of biotechnology and traditional sericulture, as Kraig Labs works to establish spider silk as a commercial reality.
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
ir@KraigLabs.com
FAQ
What is the significance of Dr. Nirmal Kumar joining KBLB's Southeast Asian facility?
What is BAM-1 and how is Kraig Biocraft Laboratories producing it?
What are Kraig Biocraft Laboratories' current commercial developments for spider silk?
Where are Kraig Biocraft Laboratories' spider silk production facilities located?
What is Kraig Biocraft Laboratories' strategy for scaling up spider silk production?
